Picosecond timing of Microwave Cherenkov Impulses from High-Energy Particle Showers Using Dielectric-loaded Waveguides

We report on the first measurements of coherent microwave impulses from high-energy particle-induced electromagnetic showers generated via the Askaryan effect in a dielectric-loaded waveguide. Bunches of 12.16 GeV electrons with total bunch energy of $\sim 10^3-10^4$ GeV were pre-showered in tungsten, and then measured with WR-51 rectangular (12.6 mm by 6.3 mm) waveguide elements loaded with solid alumina ($Al_2 O_3$) bars. In the 5-8 GHz $TE_{10}$ single-mode band determined by the presence of the dielectric in the waveguide, we observed band-limited microwave impulses with amplitude proportional to bunch energy. Signals in different waveguide elements measuring the same shower were used to estimate relative time differences with 2.3 picosecond precision. These measurements establish a basis for using arrays of alumina-loaded waveguide elements, with exceptional radiation hardness, as very high precision timing planes for high-energy physics detectors.Comment: 16 pages, 15 figure

Development Toward a Ground-Based Interferometric Phased Array for Radio Detection of High Energy Neutrinos

The in-ice radio interferometric phased array technique for detection of high energy neutrinos looks for Askaryan emission from neutrinos interacting in large volumes of glacial ice, and is being developed as a way to achieve a low energy threshold and a large effective volume at high energies. The technique is based on coherently summing the impulsive Askaryan signal from multiple antennas, which increases the signal-to-noise ratio for weak signals. We report here on measurements and a simulation of thermal noise correlations between nearby antennas, beamforming of impulsive signals, and a measurement of the expected improvement in trigger efficiency through the phased array technique. We also discuss the noise environment observed with an analog phased array at Summit Station, Greenland, a possible site for an interferometric phased array for radio detection of high energy neutrinos.Comment: 13 Pages, 14 Figure

Measurements and Modeling of Near-Surface Radio Propagation in Glacial Ice and Implications for Neutrino Experiments

We present measurements of radio transmission in the $\sim$100 MHz range through a $\sim100$ m deep region below the surface of the ice at Summit Station, Greenland, called the firn. In the firn, the index of refraction changes due to the transition from snow at the surface to glacial ice below, affecting the propagation of radio signals in that region. We compare our observations to a finite-difference time-domain (FDTD) electromagnetic wave simulation, which supports the existence of three classes of propagation: a bulk propagation ray-bending mode that leads to so-called "shadowed" regions for certain geometries of transmission, a surface-wave mode induced by the ice/air interface, and an arbitrary-depth horizontal propagation mode that requires perturbations from a smooth density gradient. In the non-shadowed region, our measurements are consistent with the bulk propagation ray-bending mode both in timing and in amplitude. We also observe signals in the shadowed region, in conflict with a bulk-propagation-only ray-bending model, but consistent with FDTD simulations using a variety of firn models for Summit Station. The amplitude and timing of our measurements in all geometries are consistent with the predictions from FDTD simulations. In the shadowed region, the amplitude of the observed signals is consistent with a best-fit coupling fraction value of $2.4$% (0.06% in power) or less to a surface or horizontal propagation mode from the bulk propagation mode. The relative amplitude of observable signals in the two regions is important for experiments that aim to detect radio emission from astrophysical high-energy neutrinos interacting in glacial ice, which rely on a radio propagation model to inform simulations and perform event reconstruction.Comment: 14 pages, 13 figures, version accepted to PR

Phase diagram and critical properties within an effective model of QCD: the Nambu-Jona-Lasinio model coupled to the Polyakov loop

We investigate the phase diagram of the so-called Polyakov--Nambu--Jona-Lasinio model at finite temperature and non-zero chemical potential with three quark flavors. Chiral and deconfinement phase transitions are discussed and the relevant order-like parameters are analyzed. The results are compared with simple thermodynamic expectations and lattice data. We present the phase diagram in the ($T,\,\mu_B)$ plane, paying special attention to the critical end point: as the strength of the flavor-mixing interaction becomes weaker, the critical end point moves to low temperatures and can even disappear.Comment: 46 pages, 11 figures, 3 table

Debye screening in strongly coupled N=4 supersymmetric Yang-Mills plasma

Using the AdS/CFT correspondence, we examine the behavior of correlators of Polyakov loops and other operators in N=4 supersymmetric Yang-Mills theory at non-zero temperature. The implications for Debye screening in this strongly coupled non-Abelian plasma, and comparisons with available results for thermal QCD, are discussed.Comment: 21 pages, 5 figures, significantly expanded discussion of Polyakov loop correlator and static quark-antiquark potentia

The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005–2019

Pneumococcal conjugate vaccines (PCVs) have lowered the incidence of invasive pneumococcal disease (IPD) worldwide. However, the influence of regional vaccine uptake differences on the changing epidemiology of IPD remains unclear. We aimed to examine the overall impact of both seven- and 13-valent PCVs (PCV7 and PCV13) on IPD in Switzerland. Three-year periods from 2005–2010 and 2011–2019 were considered, respectively, as (early and late) PCV7 eras and (early, mid and late) PCV13 eras. Vaccine coverage was estimated from a nationwide survey according to east (German-speaking) and west (French/Italian-speaking) regions for each period. Reported incidence rate ratios (IRRs) were compared between successive periods and regions using nationwide IPD surveillance data. Overall IPD incidence across all ages was only 16% lower in the late PCV13 era compared to the early PCV7 era (IRR 0.83, 95% CI 0.79–0.88), due to increasing incidence of non-PCV-type IPD (2.59, 2.37–2.83) in all age groups, except children <5 years. PCV uptake rates in swiss children were slightly higher in the west than the east (p < 0.001), and were accompanied by lower IPD incidences across all age groups in the former region. Post-PCV13, non-PCV serotypes 8, 22F and 9N were the major cause of IPD in adults ≥65 years. Increased PCV coverage in both areas of Switzerland resulted in a decrease in vaccine-type and overall IPD incidence across all age groups, in a regionally dependent manner. However, the rising incidence of non-vaccine-type IPD, exclusive to older adults, may undermine indirect beneficial effects

Accelerator measurements of magnetically-induced radio emission from particle cascades with applications to cosmic-ray air showers

For fifty years, cosmic-ray air showers have been detected by their radio emission. We present the first laboratory measurements that validate electrodynamics simulations used in air shower modeling. An experiment at SLAC provides a beam test of radio-frequency (RF) radiation from charged particle cascades in the presence of a magnetic field, a model system of a cosmic-ray air shower. This experiment provides a suite of controlled laboratory measurements to compare to particle-level simulations of RF emission, which are relied upon in ultra-high-energy cosmic-ray air shower detection. We compare simulations to data for intensity, linearity with magnetic field, angular distribution, polarization, and spectral content. In particular, we confirm modern predictions that the magnetically induced emission in a dielectric forms a cone that peaks at the Cherenkov angle and show that the simulations reproduce the data within systematic uncertainties.Comment: 5 pages, 7 figure

The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.

Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally. Patients with a histologically confirmed diagnosis of a solid tumour refractory to standard forms of therapy were eligible for the study. GI147211 was given orally on day 1 and as a 30-min infusion daily on days 2-5. The treatment course was repeated every 3 weeks. In subsequent patient cohorts, the dose of the oral formulation was escalated from 1.5 mg m(-2) to 6.0 mg m(-2); the dose for i.v. administration was fixed at 1.2 mg m(-2). Plasma pharmacokinetics was performed on day 1 and 2 of the first course and on day 1 of the second course using a validated high-performance liquid chromatographic assay. Nineteen patients were entered into the study; one patient was not evaluable because the treatment course was stopped prematurely. Eighteen patients received a total of 47 treatment courses. The absolute bioavailability of GI147211 averaged 1.3 +/- 5.2%. Drug appeared quickly in plasma with a median Tmax at 0.5 h. Fasting or fed state had no significant influence on the bioavailability of GI147211. The terminal half-life after administration of oral GI147211 was 6.85 +/- 3.13 h, similar to the half-life after intravenous administration. The major toxicities were neutropenia and thrombocytopenia. Nadirs for neutropenia and thrombocytopenia occurred on day 8 and day 15 respectively. Other toxicities predominantly consisted of mild and infrequent nausea and vomiting, and fatigue. The oral administration of the drug is well tolerated. Oral administration of topoisomerase I inhibitor GI147211 results in a low bioavailability with relatively wide interpatient variation. The intravenous route of administration is advised for further development of this promising topoisomerase I inhibitor